[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651984":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":59,"collaborators":61,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":21,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":21,"enrollmentInfo":74,"targetDuration":21,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":21,"overallStatus":83,"whyStopped":21,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Stanford University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Moisturizer","EXPERIMENTAL","Participants in this arm will apply the following cosmeceutical topical moisturizers twice daily (once in the morning and once in the evening) for the duration of the study:\n\n1. La Roche Posay Lipikar wash Atopy-Prone Plus (AP+) moisturizing face and body wash (once in the morning and once in the evening)\n2. La Roche Posay Lipikar AP+ triple repair moisturizing cream (once in the morning and once in the evening)\n3. La Roche Posay Cicaplast balm Panthenol\u002FVitamin B5 (B5+) (once in the morning and once in the evening)",[13,14,15],"Other: La Roche Posay Lipikar Wash Atopy-Prone Plus (AP+) Moisturizing Face and Body Wash","Other: La Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream","Other: La Roche Posay Cicaplast balm Panthenol\u002FVitamin B5 (B5+)",[17,22,26],{"type":6,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"La Roche Posay Lipikar Wash Atopy-Prone Plus (AP+) Moisturizing Face and Body Wash","Moisturizer wash applied once in the morning and once in the evening.",[9],null,{"type":6,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"La Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream","Moisturizer applied once in the morning and once in the evening.",[9],{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":21},"La Roche Posay Cicaplast balm Panthenol\u002FVitamin B5 (B5+)","Balm applied once in the morning and once in the evening.",[9],[31],{"name":32,"affiliation":5,"role":33},"Lisa Zaba, MD, PhD","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":21,"email":39},"Clinical Research Coordinator","CONTACT","650-497-1218","hannah05@stanford.edu",[41],{"facility":42,"status":21,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Stanford Health Care: Supportive Dermato-Oncology Program","Palo Alto","California","94304","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-122.14302,37.44188,{"lat":52,"lon":51},[55,58],{"name":56,"role":37,"phone":57,"phoneExt":21,"email":39},"Hannah Clinical Research Coordinator","650-487-1218",{"name":32,"role":33,"phone":21,"phoneExt":21,"email":21},{"type":60,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR",[62],{"name":63,"class":64},"L'Oreal","INDUSTRY","100651984","characterization-of-skin-changes-clinical-physiological-and-pathological-from-the-use-of-moisturizers-in-participants-with-cancer-experiencing-dermatological-adverse-events-100651984",false,"NCT07767448","Characterization of Skin Changes From the Use of Moisturizers in Participants With Cancer Experiencing Dermatological Adverse Events","Characterization of Skin Changes (Clinical, Physiological and Pathological) Leading to Dermatological Adverse Events From Chemotherapy, Targeted Therapy, Hormonal Therapy, and Immune Checkpoint Inhibitors","Inclusion Criteria:\n\n* Adult patient (18 years or older).\n* Patients diagnosed with cancer.\n* Patient receiving cancer treatment or therapy (receiving chemotherapy, targeted treatment, hormonal therapy, and\u002For immune checkpoint inhibitors).\n* Patient experiencing a dermatological adverse event from a cancer treatment or therapy.\n\nExclusion Criteria:\n\n* Patient is unable to understand scope of the study.\n* Patient is unable to provide written informed consent.\n* Patient is healthy.","ALL","18 Years",{"count":75,"type":76},50,"ESTIMATED","INTERVENTIONAL",[79],"NA","The goal of this clinical trial is to evaluate whether cosmeceutical topical moisturizers can help with skin dryness in participants with cancer experiencing a dermatological adverse event from cancer therapies. The main question it aims to answer is:\n\nDoes cosmeceutical topical moisturizers help with skin dryness?\n\nParticipants will:\n\n* Visit the clinic for a baseline visit to complete skin evaluation and tests.\n* Apply cosmeceutical topical moisturizers daily from baseline up until the follow-up visit.\n* Visit the clinic for a follow-up visit (approximately 2-4 weeks from baseline) for a repeat skin evaluation and tests.",[82],"Cancer","NOT_YET_RECRUITING","2026-08-19",{"date":86,"type":87},"2026-08-21","ACTUAL",{"date":89,"type":76},"2026-08",{"date":91,"type":76},"2029-02",{"name":5,"class":6},1]